Impact of Molecular Markers and Cytogenetic Abnormalities on Long-Term Overall Survival and Disease-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Acute Myeloid Leukemia (AML) patients
Mauricette Michallet(Université Claude Bernard Lyon 1), Sandrine Hayette(Hôpital Claude Huriez), Claudiu Plesa(Institut Mérieux (France)), Fiorenza Barraco(Hôpital Lyon Sud), Youcef Chelghoum(Hôpital Edouard Herriot), Jacques Troncy(Hôpital Edouard Herriot), Emmanuelle Nicolas‐Virelizier(Hôpital Edouard Herriot), Isabelle Tigaud(Inserm), Franck E. Nicolini(Université Claude Bernard Lyon 1), Mohamad Sobh(Ottawa Hospital), Jean‐Pierre Magaud(Hôpital Lyon Sud), Carole Charlot(Hôpital Edouard Herriot), Xavier Thomas(Hôpital Lyon Sud), Giovanna Cannas(Hôpital Edouard Herriot)
Cited by 0
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547